JNJ Stock Summary and Trading Ideas (Johnson & Johnson | NYSE:JNJ)

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Johnson & Johnson trades on the NYSE stock market under the symbol JNJ.

As of December 18, 2025, JNJ stock price declined to $208.31 with 6,567,202 million shares trading.

JNJ has a beta of 0.22, meaning it tends to be less sensitive to market movements. JNJ has a correlation of 0.05 to the broad based SPY ETF.

JNJ has a market cap of $501.61 billion. This is considered a Mega Cap stock.

Last quarter Johnson & Johnson reported $24 billion in Revenue and $2.80 earnings per share. This beat revenue expectation by $244 million and exceeded earnings estimates by $.04.

In the last 3 years, JNJ traded as high as $215.19 and as low as $140.68.

The top ETF exchange traded funds that JNJ belongs to (by Net Assets): VTI, VOO, IVV, SPY, VTV.

JNJ has outperformed the market in the last year with a price return of +47.5% while the SPY ETF gained +16.6%. JNJ has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +20.4% and +2.9%, respectively, while the SPY returned +2.7% and -1.2%, respectively.

JNJ support price is $207.65 and resistance is $213.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JNJ shares will trade within this expected range on the day.